Xiao D, Weng J, Zhang L, Xing C, et al. Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China. PLoS One 2025;20:e0310497.
PMID: 39913436